相似文献
1
Proton pump inhibitor use is associated with increased risk of severity and mortality from coronavirus disease 2019 (COVID-19) infection.
Dig Liver Dis. 2020 Dec;52(12):1410-1412. doi: 10.1016/j.dld.2020.10.001. Epub 2020 Oct 6.
2
Proton pump inhibitor on susceptibility to COVID-19 and its severity: a systematic review and meta-analysis.
Pharmacol Rep. 2021 Dec;73(6):1642-1649. doi: 10.1007/s43440-021-00263-x. Epub 2021 Apr 11.
3
Association Between Preadmission Acid Suppressive Medication Exposure and Severity of Illness in Patients Hospitalized With COVID-19.
Gastroenterology. 2021 Mar;160(4):1417-1422.e14. doi: 10.1053/j.gastro.2020.11.007. Epub 2020 Nov 12.
4
Does Proton Pump Inhibitor Use Lead to a Higher Risk of Coronavirus Disease 2019 Infection and Progression to Severe Disease? a Meta-analysis.
Jpn J Infect Dis. 2022 Jan 24;75(1):10-15. doi: 10.7883/yoken.JJID.2021.074. Epub 2021 May 31.
5
Lack of Consistent Associations Between Pharmacologic Gastric Acid Suppression and Adverse Outcomes in Patients With Coronavirus Disease 2019: Meta-Analysis of Observational Studies.
Gastroenterology. 2021 Jun;160(7):2588-2590.e7. doi: 10.1053/j.gastro.2021.02.028. Epub 2021 Feb 17.
6
What is the role of proton pump inhibitors consumption on the clinical presentation and severity of COVID-19 infection?
Ann Pharm Fr. 2023 Mar;81(2):210-219. doi: 10.1016/j.pharma.2022.08.013. Epub 2022 Aug 29.
7
Effects of proton pump inhibitor on outcomes of patients with severe acute pancreatitis based on a national administrative database.
Pancreatology. 2015 Sep-Oct;15(5):491-496. doi: 10.1016/j.pan.2015.07.006. Epub 2015 Aug 8.
8
Gastroesophageal reflux disease symptom severity, proton pump inhibitor use, and esophageal carcinogenesis.
Arch Surg. 2011 Jul;146(7):851-8. doi: 10.1001/archsurg.2011.174.
9
Long-term proton pump inhibitor use is a risk factor for mortality in patients hospitalized for COVID-19.
Turk J Med Sci. 2021 Aug 30;51(3):1675-1681. doi: 10.3906/sag-2103-80.
10
Reduced gastric acidity, proton pump inhibitors and increased severity of COVID-19 infections.
Crit Care. 2021 Feb 18;25(1):73. doi: 10.1186/s13054-021-03497-6.
引用本文的文献
1
Association Between the Use of Proton Pump Inhibitors and Severe Clinical Outcomes in COVID-19 Patients: A Retrospective Observational Study.
Cureus. 2024 Oct 25;16(10):e72385. doi: 10.7759/cureus.72385. eCollection 2024 Oct.
2
Proton Pump Inhibitors and Risk of COVID-19 Infection in Children.
J Pediatr. 2024 Nov;274:114179. doi: 10.1016/j.jpeds.2024.114179. Epub 2024 Jun 28.
3
Protocol implementation during the COVID-19 pandemic: experiences from a randomized trial of stress ulcer prophylaxis.
BMC Med Res Methodol. 2024 May 4;24(1):109. doi: 10.1186/s12874-024-02233-2.
4
Non-alcoholic fatty liver disease (NAFLD) and COVID-19 outcomes: A systematic review, meta-analysis, and meta-regression.
Narra J. 2023 Apr;3(1):e102. doi: 10.52225/narra.v3i1.102. Epub 2023 Apr 19.
5
Liver injury on admission linked to worse outcomes in COVID-19: an analysis of 14,138 patients.
Transl Gastroenterol Hepatol. 2023 Jan 25;8:4. doi: 10.21037/tgh-21-94. eCollection 2023.
6
Pathogenesis and Mechanisms of SARS-CoV-2 Infection in the Intestine, Liver, and Pancreas.
Cells. 2023 Jan 9;12(2):262. doi: 10.3390/cells12020262.
7
Assessment of proton-pump inhibitor use at a tertiary teaching hospital in Nigeria.
Med Access Point Care. 2021 Dec 5;5:23992026211062729. doi: 10.1177/23992026211062729. eCollection 2021 Jan-Dec.
8
Association between viral hepatitis and increased risk of severe coronavirus disease 2019 (COVID-19) outcome: a systematic review and meta-analysis.
Gastroenterol Hepatol Bed Bench. 2022 Winter;15(1):9-14.
9
The Use of Proton Pump Inhibitors and COVID-19: A Systematic Review and Meta-Analysis.
Trop Med Infect Dis. 2022 Feb 28;7(3):37. doi: 10.3390/tropicalmed7030037.
10
Use of proton pump inhibitors are associated with higher mortality in hospitalized patients with COVID-19.
J Glob Health. 2022 Feb 19;12:05005. doi: 10.7189/jogh.12.05005. eCollection 2022.
本文引用的文献
1
COVID-19 in patients with hepatobiliary and pancreatic diseases: a single-centre cross-sectional study in East London.
BMJ Open. 2021 Apr 19;11(4):e045077. doi: 10.1136/bmjopen-2020-045077.
2
Relation of severe COVID-19 to polypharmacy and prescribing of psychotropic drugs: the REACT-SCOT case-control study.
BMC Med. 2021 Feb 22;19(1):51. doi: 10.1186/s12916-021-01907-8.
3
Pre-hospitalization proton pump inhibitor use and clinical outcomes in COVID-19.
Eur J Gastroenterol Hepatol. 2022 Feb 1;34(2):137-141. doi: 10.1097/MEG.0000000000002013.
4
Statin therapy did not improve the in-hospital outcome of coronavirus disease 2019 (COVID-19) infection.
Diabetes Metab Syndr. 2020 Nov-Dec;14(6):1613-1615. doi: 10.1016/j.dsx.2020.08.023. Epub 2020 Aug 26.
5
Metformin use is associated with reduced mortality rate from coronavirus disease 2019 (COVID-19) infection.
Obes Med. 2020 Sep;19:100290. doi: 10.1016/j.obmed.2020.100290. Epub 2020 Aug 18.
6
Severe clinical outcomes of COVID-19 associated with proton pump inhibitors: a nationwide cohort study with propensity score matching.
Gut. 2021 Jan;70(1):76-84. doi: 10.1136/gutjnl-2020-322248. Epub 2020 Jul 30.
7
Fecal-oral transmission of COVID-19: Could hypochlorhydria play a role?
J Med Virol. 2021 Jan;93(1):166-167. doi: 10.1002/jmv.26265. Epub 2020 Jul 15.
8
The use of renin angiotensin system inhibitor on mortality in patients with coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis.
Diabetes Metab Syndr. 2020 Sep-Oct;14(5):983-990. doi: 10.1016/j.dsx.2020.06.047. Epub 2020 Jun 27.
9
Treatment with proton pump inhibitors increases the risk of secondary infections and ARDS in hospitalized patients with COVID-19: coincidence or underestimated risk factor?
J Intern Med. 2021 Jan;289(1):121-124. doi: 10.1111/joim.13121. Epub 2020 Jul 1.
10
Latest insights into the hot question of proton pump inhibitor safety - a narrative review.
Dig Liver Dis. 2020 Aug;52(8):842-852. doi: 10.1016/j.dld.2020.04.020. Epub 2020 Jun 6.
Zotero 插件